Sudarshan Pharma Industries Ltd
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
- Market Cap ₹ 780 Cr.
- Current Price ₹ 31.2
- High / Low ₹ 42.8 / 18.5
- Stock P/E 31.0
- Book Value ₹ 6.44
- Dividend Yield 0.00 %
- ROCE 15.1 %
- ROE 16.3 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 54.2% CAGR over last 5 years
- Company's working capital requirements have reduced from 43.9 days to 17.1 days
Cons
- Stock is trading at 4.85 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -1.12%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 148 | 193 | 357 | 461 | 464 | 505 | 703 | 732 | |
| 143 | 186 | 346 | 446 | 441 | 465 | 652 | 676 | |
| Operating Profit | 5 | 7 | 11 | 15 | 23 | 40 | 51 | 56 |
| OPM % | 3.2% | 3.7% | 3.1% | 3.2% | 4.9% | 8% | 7% | 8% |
| 0 | 0 | 0 | 1 | 3 | -0 | 9 | 9 | |
| Interest | 3 | 3 | 3 | 5 | 9 | 16 | 26 | 28 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 2 | 4 | 4 |
| Profit before tax | 2 | 4 | 7 | 9 | 15 | 22 | 31 | 33 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 26% | 23% | |
| 1 | 3 | 5 | 7 | 11 | 16 | 23 | 25 | |
| EPS in Rs | 0.09 | 0.19 | 0.36 | 0.29 | 0.48 | 0.66 | 0.97 | 1.03 |
| Dividend Payout % | -0% | -0% | -0% | 10% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 15% |
| TTM: | 33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 54% |
| 3 Years: | 48% |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 61% |
| 1 Year: | 30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 14% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 24 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 | 131 |
| 21 | 30 | 31 | 34 | 105 | 171 | 285 | |
| 18 | 47 | 77 | 97 | 67 | 100 | 202 | |
| Total Liabilities | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
| 6 | 6 | 6 | 20 | 26 | 48 | 104 | |
| CWIP | -0 | -0 | 1 | 0 | 2 | 23 | 3 |
| Investments | 0 | -0 | -0 | 12 | 14 | 30 | -0 |
| 53 | 93 | 131 | 200 | 242 | 302 | 534 | |
| Total Assets | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 1 | 3 | -4 | -29 | 6 | -32 | -2 | |
| -3 | -1 | -1 | -26 | -5 | -21 | -78 | |
| -0 | -1 | 4 | 66 | -12 | 53 | 79 | |
| Net Cash Flow | -2 | -0 | -1 | 11 | -12 | 0 | -1 |
| Free Cash Flow | -4 | 1 | -5 | -43 | 2 | -54 | -51 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 20% | 50% | -19% | -179% | 36% | -74% | 7% |
Ratios
Consolidated / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 114 | 75 | 64 | 96 | 116 | 121 |
| Inventory Days | 46 | 49 | 51 | 63 | 74 | 117 | 129 |
| Days Payable | 40 | 91 | 80 | 78 | 49 | 76 | 111 |
| Cash Conversion Cycle | 72 | 72 | 46 | 50 | 122 | 156 | 139 |
| Working Capital Days | 35 | 29 | 27 | 54 | 62 | 52 | 17 |
| ROCE % | 15% | 19% | 15% | 14% | 16% | 15% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Export Revenue as % of Total Revenue % |
|
|||||
| Number of Exporting Countries count |
||||||
| Number of Subsidiaries count |
||||||
| Creditor Days days |
||||||
| Net Working Capital Days days |
||||||
| Manufacturing Revenue as % of Total Revenue % |
||||||
Extracted by Screener AI
Documents
Announcements
-
Updates On Migration From SME Platform Of BSE To Capital Market Segment (Main Board) Of National Stock Exchange Of India Limited Of Sudarshan Pharma Industries Limited - Company Letter Bearing Ref. No. SPIL/CS/SE/2026-2027/20 Dated 21St May 2026
- NSE approved listing of equity shares on main board from October 27, 2026.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
- Proposal to acquire 9.50% stake in Med Therapy Biotechnology Inc. terminated.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificates for quarter ended 30 September 2026.
-
Closure of Trading Window
- Trading window closed from 1 October 2026 until 48 hours after Q2 FY2026-27 results.
-
Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
- Sold 51% stake in Ishwari Healthcare for Rs 1.40 crore; it ceased to be a subsidiary.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
Business Overview:[1][2]
SPIL does jobwork manufacturing in pharmaceutical Items and trading in chemicals and solvents in India. It
specializes in a host of products from rock chemicals intermediates and API to finish formulations and fully
integrated pharmaceutical and chemicals